A Phase 2/3 interventional study of moxidectin (8 mg) / albendazole (400 mg) and ivermectin (200 µg/kg) / albendazole (400 mg) in Trichuriasis, Ascariasis and Hookworm Infections, sponsored by Jennifer Keiser. Completed at 1 site in Tanzania. Open to participants aged 12 Years to 19 Years. Per ClinicalTrials.gov, last updated 2024-12-05.
Sponsored by Jennifer Keiser · Phase 2/3, Interventional, and Treatment
The aim of this randomized controlled trial is to provide evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to co-administered ivermectin and albendazole, and to assess the efficacy of the drug combinations compared to monotherapies in adolescents aged 12-19 years against infection with T. trichiura.
The efficacy of the different treatments will be determined 14-21 days, 5-6 weeks and 3 months post-treatment. Two fecal samples will be collected at each time-point assessment. The geometric mean based egg reduction rate (ERR) of T. trichiura egg counts will be assessed by Kato-Katz microscopy pre-treatment and 14-21 days post-treatment.
This trial will be conducted as a school-based study on Pemba Island (Zanzibar, Tanzania).
We designed a non-inferiority trial to show that co-administered moxidectin and albendazole is non-inferior compared to co-administered ivermectin and albendazole in adolescents aged 12-19 years on Pemba Island (Tanzania). From previous studies conducted by our group, we expect similar efficacies from the combination moxidectin/ albendazole compared to ivermectin/ albendazole. However, moxidectin might be advantageous in terms of the drug's longer half-life and in areas with possible emerging ivermectin resistance. This study will allow comparing the efficacy of the two available co-administrations and will provide further insights on the potential value of moxidectin/ albendazole. Our data will pave the way for possible large scale, multi country follow-up studies. As recommended for new combination therapies, we simultaneously assess superiority of the drug combinations compared to monotherapies.
The primary objective is to demonstrate that co-administered moxidectin (8 mg) / albendazole (400 mg) is non-inferior to ivermectin (200 µg/kg) / albendazole (400 mg) in terms of egg reduction rates (ERRs) against T. trichiura infections assessed by Kato-Katz at 14-21 days post-treatment in adolescents aged 12-19 years using a non-inferiority margin of 2 percentage-points.
The secondary objectives of the trial are:
The study will be carried out in adolescents aged 12-19 years attending secondary schools on Pemba Island, Tanzania. After consenting, all participants will be asked to provide two stool samples (within a maximum of 7 days) at each time-point assesment. From each stool specimen, duplicate Kato-Katz thick smears (41.7 mg each) will be prepared and read under a microscope for eggs of T. trichiura, A. lumbricoides and hookworm by experienced technicians.
After randomization, all eligible adolescents will be treated with the respective single or combination treatment regimen according to their assigned treatment arm at day 0.
All drugs will be administered in the presence of the PI and/ co-PI, and ingestion confirmed. This will be recorded with the time and date of dosing. Participants will be kept for 3 hours after treatment administration to observe any possible acute AEs and reassessment will be done at 24h post-treatment. Additionally, interviews will be conducted to determine the emergence of clinical symptoms such as headache, abdominal pain, itching, nausea, vomiting and diarrhea directly before treatment within the scope of baseline assessment. At 3 and 24 hours after treatment and retrospectively at days 14 - 21 as well as 5-6 weeks and 3 months post-treatment, participants will again be interviewed for the assessment of adverse events (AEs).
Egg reduction rate calculated from the geometric means of co-administered moxidectin/ albendazole and ivermectin/ albendazole against T. trichiura assessed at 14-21 days post-treatment is the primary endpoint in our study.
Exclusion Criteria:
Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Drug: moxidectin (8 mg) / albendazole (400 mg)
Combination therapy of ivermectin (Stromectol®, 200 µg/kg using 3 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Drug: ivermectin (200 µg/kg) / albendazole (400 mg)
Monotherapy of albendazole (400 mg) administered orally at day 0 Other names: Zentel®
Drug: ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
Monotherapy of ivermectin ( 200 µg/kg using 3 mg tablets) administered orally at day 0 Other names: Stromectol®
Drug: ivermectin (200 µg/kg)
Monotherapy of moxidectin (8 mg using 2 mg tablets) administered orally at day 0
Drug: moxidectin (8 mg)
Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Also known as: Zentel®
Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Also known as: Stromectol® / Zentel®
Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Also known as: Zentel®
Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
Also known as: Stromectol®
Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
Egg Reduction Rate Against T. Trichiura
Egg reduction rate is calculated as the relative reduction in the group geometric mean egg output after co-administration of moxidectin/ albendazole and ivermectin/ albendazole assessed at 14-21 days post-treatment compared to the baseline levels.
Time frame: 14-21 day post-treatment
Number of Participants With Adverse Events
The observation time for AE starts when the treatment is initiated. Subjects will be kept for observation for at least 3 hours following treatment for any acute AE and. If there is any abnormal finding, the local study physician will perform a full clinical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. Participants will also be interviewed at 3h and 24h as well as retrospectively 14 -21 days, 5-6 weeks and 3 months after treatment about the occurrence of AEs.
Time frame: 3 hours, 24 hours, 14-21 days, 5-6 weeks and 3 months post-treatment
Superiority in Terms of Cure Rates (CRs)
Assessment of superiority in terms of CRs of the drug combinations compared to their corresponding monotherapies: Arm C: Albendazole (400 mg) Arm D: Ivermectin (200 μg/kg) and Arm E: Moxidectin (8 mg). Cure rates is defined as the percentages of participants treated with Moxidectin (8 mg)/Albendazole (400 mg), Ivermectin (200 μg/kg)/Albendazole (400 mg), Albendazole (400 mg), Ivermectin (200 μg/kg) or Moxidectin (8 mg) who were cured of infections with T. trichiura.
Time frame: 14-21 day post-treatment
Cure Rates Against T. Trichiura
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 14-21 day post-treatment
Extended Effects (Egg Reduction Rate) on Follow-up of T. Trichiura: 5-6 Weeks
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 5-6 weeks post-treatment
Extended Effects (Cure Rate) on Follow-up of T. Trichiura: 5-6 Weeks
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 5-6 weeks post-treatment
Extended Effects (Egg Reduction Rate) on Follow-up of T. Trichiura: 3 Months
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 3 months post-treatment
Extended Effects (Cure Rates) on Follow-up of T. Trichiura: 3 Months
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 3 months post-treatment
Egg Reduction Rates Against Concomitant Soil-transmitted Helminth Infections: Hookworm
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 14-21 days post-treatment
Cure Rates Against Concomitant Soil-transmitted Helminth Infections: Hookworm
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 14-21 days post-treatment
Extended Effects (Egg Reduction Rate) on Follow-up of Hookworm: 5-6 Weeks
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 5-6 weeks post-treatment
Extended Effects (Cure Rate) on Follow-up of Hookworm: 5-6 Weeks
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 5-6 weeks post-treatment
Extended Effects (Egg Reduction Rate) on Follow-up of Hookworm: 3 Months
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 3 months post-treatment
Extended Effects (Cure Rate) on Follow-up of Hookworm: 3 Months
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 3 months post-treatment
Egg Reduction Rates Against Concomitant Soil-transmitted Helminth Infections: Ascaris Lumbricoides
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 14-21 days post-treatment
Cure Rates Against Concomitant Soil-transmitted Helminth Infections: Ascaris Lumbricoides
Cure rates is defined as the percentages of participants treated with Moxidectin (8 mg)/Albendazole (400 mg), Ivermectin (200 μg/kg)/Albendazole (400 mg), Albendazole (400 mg), Ivermectin (200 μg/kg) or Moxidectin (8 mg) who were cured of infections with A. lumbricoides.
Time frame: 14-21 days post-treatment
Extended Effects (Egg Reduction Rate) on Follow-up of A. Lumbricoides: 5-6 Weeks
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 5-6 weeks post-treatment
Extended Effects (Cure Rate) on Follow-up of A. Lumbricoides: 5-6 Weeks
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 5-6 weeks post-treatment
Extended Effects (Egg Reduction Rate) on Follow-up of A. Lumbricoides: 3 Months
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
Time frame: 3 months post-treatment
Extended Effects (Cure Rate) on Follow-up of A. Lumbricoides: 3 Months
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Time frame: 3 months post-treatment
| Milestone | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Started | 207 | 211 | 19 | 19 | 80 |
| Completed | 207 | 211 | 19 | 19 | 80 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Started | 207 | 211 | 19 | 19 | 80 |
| Completed | 207 | 211 | 19 | 19 | 80 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Started | 207 | 211 | 19 | 19 | 80 |
| Completed | 206 | 211 | 18 | 19 | 80 |
| Not completed | 1 | 0 | 1 | 0 | 0 |
| Milestone | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Started | 206 | 211 | 18 | 19 | 80 |
| Completed | 201 | 210 | 18 | 18 | 77 |
| Not completed | 5 | 1 | 0 | 1 | 3 |
Egg reduction rate is calculated as the relative reduction in the group geometric mean egg output after co-administration of moxidectin/ albendazole and ivermectin/ albendazole assessed at 14-21 days post-treatment compared to the baseline levels.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Egg Reduction Rate Against T. Trichiura | 96.8 (95.8 to 97.6) | 99.0 (98.7 to 99.3) | 86.2 (61.8 to 95.6) | 94.2 (89.3 to 97.1) | 85.5 (79.7 to 89.8) |
The observation time for AE starts when the treatment is initiated. Subjects will be kept for observation for at least 3 hours following treatment for any acute AE and. If there is any abnormal finding, the local study physician will perform a full clinical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. Participants will also be interviewed at 3h and 24h as well as retrospectively 14 -21 days, 5-6 weeks and 3 months after treatment about the occurrence of AEs.
| Participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Baseline | 7 | 9 | 0 | 0 | 0 |
| 3h post treatment | 17 | 25 | 0 | 2 | 6 |
| 24h post treatment | 36 | 40 | 3 | 2 | 6 |
| 14 to 21 days post treatment | 35 | 41 | 4 | 4 | 13 |
| 5 to 6 weeks post treatment | 20 | 10 | 2 | 2 | 6 |
| 3 months post treatment | 10 | 15 | 0 | 2 | 4 |
Assessment of superiority in terms of CRs of the drug combinations compared to their corresponding monotherapies: Arm C: Albendazole (400 mg) Arm D: Ivermectin (200 μg/kg) and Arm E: Moxidectin (8 mg). Cure rates is defined as the percentages of participants treated with Moxidectin (8 mg)/Albendazole (400 mg), Ivermectin (200 μg/kg)/Albendazole (400 mg), Albendazole (400 mg), Ivermectin (200 μg/kg) or Moxidectin (8 mg) who were cured of infections with T. trichiura.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Superiority in Terms of Cure Rates (CRs) | 34.3 (27.9 to 41.2) | 54.0 (47.1 to 60.9) | 26.3 (9.1 to 51.2) | 10.5 (1.3 to 33.1) | 11.2 (5.3 to 20.3) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Cure Rates Against T. Trichiura | 34.3 (27.9 to 41.2) | 54.0 (47.1 to 60.9) | 26.3 (9.1 to 51.2) | 10.5 (1.3 to 33.1) | 11.2 (5.3 to 20.3) |
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Egg Reduction Rate) on Follow-up of T. Trichiura: 5-6 Weeks | 97.0 (96.0 to 97.8) | 98.3 (97.6 to 98.7) | 75.7 (40.8 to 90.5) | 76.9 (65.6 to 84.7) | 85.4 (77.6 to 90.7) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Cure Rate) on Follow-up of T. Trichiura: 5-6 Weeks | 37.4 (30.8 to 44.4) | 46.4 (39.6 to 53.4) | 16.7 (3.6 to 41.4) | 0.0 (0.0 to 17.6) | 11.2 (5.3 to 20.3) |
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Egg Reduction Rate) on Follow-up of T. Trichiura: 3 Months | 93.2 (90.8 to 95.0) | 97.1 (96.1 to 97.9) | 78.2 (55.5 to 90.0) | 55.4 (22.3 to 74.2) | 71.9 (58.9 to 81.4) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Cure Rates) on Follow-up of T. Trichiura: 3 Months | 27.4 (21.3 to 34.1) | 39.5 (32.9 to 46.5) | 11.1 (1.4 to 34.7) | 0.0 (0.0 to 18.5) | 9.1 (3.7 to 17.8) |
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Egg Reduction Rates Against Concomitant Soil-transmitted Helminth Infections: Hookworm | 98.8 (97.6 to 99.4) | 97.4 (95.9 to 98.4) | 100.0 (100.0 to 100.0) | 61.9 (-8.0 to 86.8) | 81.2 (58.9 to 91.7) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Cure Rates Against Concomitant Soil-transmitted Helminth Infections: Hookworm | 75.0 (62.6 to 85.0) | 62.9 (50.5 to 74.1) | 100.0 (29.2 to 100.0) | 25.0 (3.2 to 65.1) | 32.1 (15.9 to 52.4) |
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Egg Reduction Rate) on Follow-up of Hookworm: 5-6 Weeks | 98.6 (97.4 to 99.3) | 96.8 (94.9 to 98.1) | 94.6 (56.9 to 100.0) | 57.9 (-10.4 to 84.3) | 88.7 (71.0 to 95.9) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Cure Rate) on Follow-up of Hookworm: 5-6 Weeks | 71.9 (59.2 to 82.4) | 61.4 (49.0 to 72.8) | 66.7 (9.4 to 99.2) | 25.0 (3.2 to 65.1) | 42.9 (24.5 to 62.8) |
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Egg Reduction Rate) on Follow-up of Hookworm: 3 Months | 97.6 (95.9 to 98.7) | 95.1 (91.5 to 97.3) | 96.3 (83.6 to 100.0) | 56.1 (-31.9 to 85.5) | 76.7 (39.3 to 92.0) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Cure Rate) on Follow-up of Hookworm: 3 Months | 66.1 (53.0 to 77.7) | 60.0 (47.6 to 71.5) | 66.7 (9.4 to 99.2) | 25.0 (3.2 to 65.1) | 32.0 (14.9 to 53.5) |
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Egg Reduction Rates Against Concomitant Soil-transmitted Helminth Infections: Ascaris Lumbricoides | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
Cure rates is defined as the percentages of participants treated with Moxidectin (8 mg)/Albendazole (400 mg), Ivermectin (200 μg/kg)/Albendazole (400 mg), Albendazole (400 mg), Ivermectin (200 μg/kg) or Moxidectin (8 mg) who were cured of infections with A. lumbricoides.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Cure Rates Against Concomitant Soil-transmitted Helminth Infections: Ascaris Lumbricoides | 100.0 (96.6 to 100.0) | 96.4 (91.0 to 99.0) | 91.7 (61.5 to 99.8) | 100.0 (76.8 to 100.0) | 98.0 (89.4 to 99.9) |
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Egg Reduction Rate) on Follow-up of A. Lumbricoides: 5-6 Weeks | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Cure Rate) on Follow-up of A. Lumbricoides: 5-6 Weeks | 100.0 (100.00 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 98.0 (89.4 to 99.9) |
Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
| Percent change | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Egg Reduction Rate) on Follow-up of A. Lumbricoides: 3 Months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (99.9 to 100.0) | 100.0 (99.9 to 100.0) | 100.0 (99.9 to 100.0) |
Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
| Percentage of participants | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| Extended Effects (Cure Rate) on Follow-up of A. Lumbricoides: 3 Months | 87.3 (79.2 to 93.0) | 88.2 (80.6 to 93.6) | 91.7 (61.5 to 99.8) | 92.9 (66.1 to 99.8) | 87.5 (74.8 to 95.3) |
Collected over Adverse events were assessed 3h and 24h post-treatment. At the three follow-up timepoints of 14-21 days, 5-6 weeks, and 3 months after treatment, adverse events were assessed retrospectively. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A: Moxidectin (8 mg) / Albendazole (400 mg) | 0/207 (0%) | 0/207 (0%) | 73/207 (35.3%) |
| B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | 0/211 (0%) | 0/211 (0%) | 93/211 (44.1%) |
| C: Albendazole (400 mg) | 0/19 (0%) | 0/19 (0%) | 4/19 (21.1%) |
| D: Ivermectin (200 µg/kg) | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| E: Moxidectin (8 mg) | 0/80 (0%) | 0/80 (0%) | 23/80 (28.8%) |
| Event | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) |
|---|---|---|---|---|---|
| HeadacheGeneral disorders | 30/207 | 38/211 | 3/19 | 2/19 | 6/80 |
| Abdominal painGeneral disorders | 13/207 | 16/211 | 1/19 | 1/19 | 4/80 |
| ItchingGeneral disorders | 4/207 | 8/211 | 0/19 | 1/19 | 1/80 |
| Musculoskeletal painGeneral disorders | 6/207 | 6/211 | 0/19 | 1/19 | 3/80 |
| RashGeneral disorders | 2/207 | 4/211 | 0/19 | 1/19 | 0/80 |
| Muscle weaknessGeneral disorders | 6/207 | 9/211 | 0/19 | 0/19 | 4/80 |
| VomitingGeneral disorders | 1/207 | 0/211 | 0/19 | 0/19 | 2/80 |
| DiarrheaGeneral disorders | 1/207 | 5/211 | 0/19 | 0/19 | 1/80 |
| NauseaGeneral disorders | 3/207 | 3/211 | 0/19 | 0/19 | 1/80 |
| ConstipationGeneral disorders | 3/207 | 1/211 | 0/19 | 0/19 | 0/80 |
| Age, Continuous(years) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Mean | 15.8 ± 1.5 | 15.8 ± 1.5 | 15.6 ± 1.2 | 15.9 ± 1.3 | 15.8 ± 1.4 | 15.8 ± 1.5 |
| Sex: Female, Male(Participants) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Female | 148 | 163 | 13 | 16 | 54 | 394 |
| Male | 59 | 48 | 6 | 3 | 26 | 142 |
| Race and Ethnicity Not Collected(Participants) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | 0 |
| Height, cm(cm) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Mean | 157.1 ± 7.4 | 157.2 ± 7.3 | 159.1 ± 7.8 | 158.9 ± 7.1 | 157.4 ± 6.8 | 157.3 ± 7.3 |
| Weight, kg(kg) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Mean | 48.3 ± 8.3 | 47.7 ± 8.2 | 50.8 ± 7.8 | 48.1 ± 6.1 | 47.1 ± 6.5 | 48.0 ± 7.9 |
| T. trichiura infection, geometric mean EPG(eggs per gram) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Geometric mean | 450 ± 4 | 468 ± 4 | 421 ± 4 | 573 ± 4 | 481 ± 3 | 463 ± 4 |
| T. trichiura infection, arithmetic mean EPG(eggs per gram) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Mean | 975 ± 1329 | 1045 ± 1509 | 1014 ± 1504 | 1670 ± 3243 | 935 ± 1435 | 1022 ± 1525 |
| T. trichiura infection intensity (EPG): light(Participants) | A: Moxidectin (8 mg) / Albendazole (400 mg) | B: Ivermectin (200 µg/kg) / Albendazole (400 mg) | C: Albendazole (400 mg) | D: Ivermectin (200 µg/kg) | E: Moxidectin (8 mg) | Total |
|---|---|---|---|---|---|---|
| Count of participants | 144 | 148 | 14 | 14 | 57 | 377 |
12 further baseline measures are reported on the registry.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jennifer Keiser